A flurry of mergers and acquisitions in the pharma space at the end of 2023 ended with a $295 million deal by Roche to buy a point-of-care diagnostics platform from LumiraDx, which recently went into administration.Roche is buying “select parts” of the London, UK-based LumiraDx group – which has developed a microfluidics-based diagnostics platform that […]
